About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 13 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, two long-acting technologies, two experimental oral antiviral treatments for COVID-19 and a COVID-19 serological antibody diagnostic test.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, and SDC.
Featured
Technology Transfer Hub
05 October 2021
Access to Medicines Tracker
02 March 2020
Long-acting Therapeutics
02 March 2020
VaxPaL
08 June 2021
Discover MedsPaL
MedsPaL, MPP’s medicines patents and licences database, is a free resource that provides information on the intellectual property status of selected patented essential medicines in low- and middle-income countries.
MPP in Numbers
patent holders with MPP signed agreements
generic manufactures and product developers have sublicenses from MPP
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in January 2022 (data as of 30 September 2021) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Impact Stories
How access to antiretrovirals is building the future
Key Publications
Prioritising Medicines for Licensing
02 March 2020
Twitter Feed
Jayasree Iyer @JayasreeKIyer
Generic med manufacturers are vital in ensuring access to essential meds. Exciting progress has been made by @MedsPatentPool and 20+ generic co.s in bringing COVID-19 meds to millions living in #LMICs @Manica_amr @mpkieny @Maybarduk @jarottingen @mariangelasimao @VolginaSasha https://t.co/7Nd3GZ6lnZ
MedicinesPatentPool @MedsPatentPool
The companies that were offered the #molnupiravir sublicence by MPP successfully demonstrated their ability to: ✅🏭💊meet MPP’s requirements on production capacity & regulatory compliance ✅🌍👩🏽⚕️💊meet int'l standards for quality-assured #meds. 👉🏽https://t.co/2U0vRVoCqQ #COVID19 https://t.co/BRh0otuNk1
Charles Gore @CharlieGore
👏This is a critical step toward ensuring global access to an urgently needed #COVID19 treatment and we are confident that, as manufacturers are working closely with regulatory authorities, the anticipated treatments will be rapidly available in #LMICs. https://t.co/PuUeVMU6Ix
MedicinesPatentPool @MedsPatentPool
#NEWS #COVID19 🤩 27 generic manufacturers sign agreements with MPP to produce low-cost versions of COVID-19 antiviral medication #molnupiravir for supply in 105 #LMICs. 🗞️Read our statement👉https://t.co/5aEtGv9gE1 #access2meds #PublicHealth #GlobalHealth https://t.co/y7KOx86YVe
WHO African Region @WHOAFRO
"The #COVID19 virus has evolved & formed new variants, some of which have been extremely virulent & deadly. We are now wrestling with the fast-spreading #Omicron variant." Dr @SalamGueye shares update on the Omicron variant, which has now been detected in 30 African countries. https://t.co/9U9Hkgx8w5